-
Signature
-
/s/ Alphonse Valbrune, as Attorney-in-Fact, for Jim Cox
-
Issuer symbol
-
CWAN
-
Transactions as of
-
15 Oct 2025
-
Transactions value $
-
-$318,690
-
Form type
-
4
-
Filing time
-
16 Oct 2025, 19:26:59 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Cox James S |
Chief Financial Officer |
C/O CLEARWATER ANALYTICS HOLDINGS, INC., 777 W. MAIN STREET, SUITE 900, BOISE |
/s/ Alphonse Valbrune, as Attorney-in-Fact, for Jim Cox |
15 Oct 2025 |
0001441361 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CWAN |
Class A Common Stock |
Options Exercise |
$74.4K |
+16.9K |
+4.91% |
$4.40 |
361K |
15 Oct 2025 |
Direct |
|
| transaction |
CWAN |
Class A Common Stock |
Sale |
-$112K |
-6.28K |
-1.74% |
$17.92 |
355K |
15 Oct 2025 |
Direct |
F1 |
| transaction |
CWAN |
Class A Common Stock |
Tax liability |
-$190K |
-10.6K |
-3% |
$17.92 |
344K |
15 Oct 2025 |
Direct |
F2 |
| transaction |
CWAN |
Class A Common Stock |
Sale |
-$90.2K |
-5K |
-1.45% |
$18.05 |
339K |
15 Oct 2025 |
Direct |
F1, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CWAN |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-16.9K |
-5.86% |
$0.00 |
272K |
15 Oct 2025 |
Class A Common Stock |
16.9K |
$4.40 |
Direct |
F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: